Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Johnson and Johnson
Harvard Business School
AstraZeneca
Colorcon

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

Litigation Details for Kissei Pharmaceutical Co. Ltd. v. Hetero USA Inc. (D. Del. 2013)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Kissei Pharmaceutical Co. Ltd. v. Hetero USA Inc. (D. Del. 2013)

Docket   Start Trial Date Filed 2013-06-17
Court District Court, D. Delaware Date Terminated 2015-01-05
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand None Referred To
Parties ACTAVIS INC.; HETERO LABS LIMITED; HETERO LABS LIMITED, UNIT III; HETERO USA INC.,; KISSEI PHARMACEUTICAL CO. LTD.; WATSON LABORATORIES INC.
Patents 5,387,603
Attorneys Brian Kao; Gary E. Hood; Jason James Rawnsley; Jeremy A. Tigan; Kaede Toh; Louis E. Fogel; Mark T. Deming; Mary Matterer; Maxwell A. Fox; Richard T. McCaulley; Rodger Dallery Smith , II; Steven J. Fineman
Link to Docket External link to docket
Small Molecule Drugs cited in Kissei Pharmaceutical Co. Ltd. v. Hetero USA Inc.
The small molecule drug covered by the patent cited in this case is   Start Trial .

Details for Kissei Pharmaceutical Co. Ltd. v. Hetero USA Inc. (D. Del. 2013)

Date Filed Document No. Description Snippet Link To Document
2013-06-17 1 the owner and assignee of U.S. Patent No. 5,387,603 (“the ‘603 patent”). 3. Actavis, Inc… (Infringement of U.S. Patent No. 5,387,603) 38. Plaintiffs expressly incorporate… (Declaratory Judgment as to U.S. Patent No. 5,387,603) 47. Plaintiffs expressly incorporate…A. The ‘603 Patent 24. On February 7, 1995, the United States Patent and Trademark Office…the assignee of the ‘603 patent. A true and accurate copy of the ‘603 patent is attached as Exhibit A External link to document
2013-06-17 3 Received Notice: 5/13/13. Date of Expiration of Patent: (5,387,603 = 12/1/18).Thirty Month Stay Deadline: 4/… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …2013 5 January 2015 1:13-cv-01091 830 Patent None District Court, D. Delaware External link to document
2013-06-17 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,387,603. (rwc) (Entered: 06…2013 5 January 2015 1:13-cv-01091 830 Patent None District Court, D. Delaware External link to document
2015-01-05 59 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,387,603. (ntl) (Entered: 01…2013 5 January 2015 1:13-cv-01091 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Dow
Boehringer Ingelheim
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.